Where this LCD applies
Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.
| Contract | Contractor | Type | States |
|---|---|---|---|
| 06101 | Wellpoint Federal | MAC - Part A | IL |
| 06201 | Wellpoint Federal | MAC - Part A | MN |
| 06301 | Wellpoint Federal | MAC - Part A | WI |
| 06102 | Wellpoint Federal | MAC - Part B | IL |
| 06202 | Wellpoint Federal | MAC - Part B | MN |
| 06302 | Wellpoint Federal | MAC - Part B | WI |
| 13101 | Wellpoint Federal | A and B and HHH MAC | CT |
| 13201 | Wellpoint Federal | A and B and HHH MAC | NY |
| 13102 | Wellpoint Federal | A and B and HHH MAC | CT |
| 13202 | Wellpoint Federal | A and B and HHH MAC | NY |
| 13282 | Wellpoint Federal | A and B and HHH MAC | NY |
| 13292 | Wellpoint Federal | A and B and HHH MAC | NY |
| 14411 | Wellpoint Federal | A and B and HHH MAC | RI |
| 14211 | Wellpoint Federal | A and B and HHH MAC | MA |
| 14311 | Wellpoint Federal | A and B and HHH MAC | NH |
| 14511 | Wellpoint Federal | A and B and HHH MAC | VT |
| 14111 | Wellpoint Federal | A and B and HHH MAC | ME |
| 14112 | Wellpoint Federal | A and B and HHH MAC | ME |
| 14212 | Wellpoint Federal | A and B and HHH MAC | MA |
| 14312 | Wellpoint Federal | A and B and HHH MAC | NH |
| 14512 | Wellpoint Federal | A and B and HHH MAC | VT |
| 14412 | Wellpoint Federal | A and B and HHH MAC | RI |
Billing and coding articles A52370, A52399, A52420 and 7 more: diagnoses and procedure codes
Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A52370 (Billing and Coding: Bevacizumab and biosimilars), Billing and Coding A52399 (Billing and Coding: Denosumab (Prolia®, Xgeva®, Jubbonti®) and biosimilars), Billing and Coding A52420 (Billing and Coding: Hyaluronans Intra-articular Injections of), Billing and Coding A52421 (Billing and Coding: Ibandronate Sodium), Billing and Coding A52423 (Billing and Coding: Infliximab and biosimilars), Billing and Coding A52448 (Billing and Coding: Omalizumab and biosimilar, OMLYCLO® (omalizumab-igec)), Billing and Coding A52450 (Billing and Coding: Paclitaxel (e.g., Taxol®/Abraxane ™)), Billing and Coding A52451 (Billing and Coding: Ranibizumab, Aflibercept and biosimilars), Billing and Coding A52453 (Billing and Coding: Luteinizing Hormone-Releasing Hormone (LHRH) Analogs), Billing and Coding A54548 (Billing and Coding: Eculizumab, and Biosimilars: EPYSQLI®-eculizumab-aagh, and BKEMV™-eculizumab-aeeb) carry the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.
Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.
A52370: Billing and Coding: Bevacizumab and biosimilars (Billing and Coding, effective 2026-07-01)
- Covered ICD-10-CM codes
- 458
- 2 groups
- Non-covered ICD-10-CM codes
- 0
- Procedure codes listed
- 9
- Full article
- cms.gov record
| ICD-10-CM | Description (FY2027) |
|---|---|
| C17.0 | Malignant neoplasm of duodenum |
| C17.1 | Malignant neoplasm of jejunum |
| C17.2 | Malignant neoplasm of ileum |
| C17.3 | Meckel's diverticulum, malignant |
| C17.8 | Malignant neoplasm of overlapping sites of small intestine |
| C17.9 | Malignant neoplasm of small intestine, unspecified |
| C18.0 | Malignant neoplasm of cecum |
| C18.1 | Malignant neoplasm of appendix |
| C18.2 | Malignant neoplasm of ascending colon |
| C18.3 | Malignant neoplasm of hepatic flexure |
| C18.4 | Malignant neoplasm of transverse colon |
| C18.5 | Malignant neoplasm of splenic flexure |
| C18.6 | Malignant neoplasm of descending colon |
| C18.7 | Malignant neoplasm of sigmoid colon |
| C18.8 | Malignant neoplasm of overlapping sites of colon |
| C18.9 | Malignant neoplasm of colon, unspecified |
| C19 | Malignant neoplasm of rectosigmoid junction |
| C20 | Malignant neoplasm of rectum |
| C21.2 | Malignant neoplasm of cloacogenic zone |
| C21.8 | Malignant neoplasm of overlapping sites of rectum, anus and anal canal |
| C22.0 | Liver cell carcinoma |
| C22.3 | Angiosarcoma of liver |
| C22.8 | Malignant neoplasm of liver, primary, unspecified as to type |
| C22.9 | Malignant neoplasm of liver, not specified as primary or secondary |
Procedure codes: 67028, C9257 (Injection, bevacizumab, 0.25 mg), J3590 (Unclassified biologics), J9035 (Injection, bevacizumab, 10 mg), Q5107 (Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg), Q5118 (Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg), Q5126 (Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg), Q5129 (Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg), Q5160 (Injection, bevacizumab-nwgd (jobevne), biosimilar, 10 mg).
A52399: Billing and Coding: Denosumab (Prolia®, Xgeva®, Jubbonti®) and biosimilars (Billing and Coding, effective 2026-10-01)
- Covered ICD-10-CM codes
- 434
- 2 groups
- Non-covered ICD-10-CM codes
- 0
- Procedure codes listed
- 11
- Full article
- cms.gov record
| ICD-10-CM | Description (FY2027) |
|---|---|
| C33 | Malignant neoplasm of trachea |
| C34.00 | Malignant neoplasm of unspecified main bronchus |
| C34.01 | Malignant neoplasm of right main bronchus |
| C34.02 | Malignant neoplasm of left main bronchus |
| C34.10 | Malignant neoplasm of upper lobe, unspecified bronchus or lung |
| C34.11 | Malignant neoplasm of upper lobe, right bronchus or lung |
| C34.12 | Malignant neoplasm of upper lobe, left bronchus or lung |
| C34.2 | Malignant neoplasm of middle lobe, bronchus or lung |
| C34.30 | Malignant neoplasm of lower lobe, unspecified bronchus or lung |
| C34.31 | Malignant neoplasm of lower lobe, right bronchus or lung |
| C34.32 | Malignant neoplasm of lower lobe, left bronchus or lung |
| C34.80 | Malignant neoplasm of overlapping sites of unspecified bronchus and lung |
| C34.81 | Malignant neoplasm of overlapping sites of right bronchus and lung |
| C34.82 | Malignant neoplasm of overlapping sites of left bronchus and lung |
| C34.90 | Malignant neoplasm of unspecified part of unspecified bronchus or lung |
| C34.91 | Malignant neoplasm of unspecified part of right bronchus or lung |
| C34.92 | Malignant neoplasm of unspecified part of left bronchus or lung |
| C40.01 | Malignant neoplasm of scapula and long bones of right upper limb |
| C40.02 | Malignant neoplasm of scapula and long bones of left upper limb |
| C40.11 | Malignant neoplasm of short bones of right upper limb |
| C40.12 | Malignant neoplasm of short bones of left upper limb |
| C40.21 | Malignant neoplasm of long bones of right lower limb |
| C40.22 | Malignant neoplasm of long bones of left lower limb |
| C40.31 | Malignant neoplasm of short bones of right lower limb |
Procedure codes: J0897 (Injection, denosumab, 1 mg), Q5136 (Injection, denosumab-bbdz (jubbonti/wyost), biosimilar, 1 mg), Q5157 (Injection, denosumab-bmwo (stoboclo/osenvelt), biosimilar, 1 mg), Q5158 (Injection, denosumab-bnht (bomyntra/conexxence), biosimilar, 1 mg), Q5159 (Injection, denosumab-dssb (ospomyv/xbryk), biosimilar, 1 mg), Q5162 (Injection, denosumab-nxxp (bildyos/bilprevda), biosimilar, 1 mg), Q5165 (Injection, denosumab-mobz (oziltus), biosimilar, 1 mg), Q5166 (Injection, denosumab-desu (osvyrti/jubereq), biosimilar, 1 mg), Q5167 (Injection, denosumab-qbde (enoby/xtrenbo), biosimilar, 1 mg), Q5171 (Injection, denosumab-mobz (boncresa), biosimilar, 1 mg), Q5173 (Injection, denosumab-adet (ponlimsi), biosimilar, 1 mg).
A52420: Billing and Coding: Hyaluronans Intra-articular Injections of (Billing and Coding, effective 2026-04-01)
- Covered ICD-10-CM codes
- 17
- 1 group
- Non-covered ICD-10-CM codes
- 0
- Procedure codes listed
- 15
- Full article
- cms.gov record
| ICD-10-CM | Description (FY2027) |
|---|---|
| M17.0 | Bilateral primary osteoarthritis of knee |
| M17.11 | Unilateral primary osteoarthritis, right knee |
| M17.12 | Unilateral primary osteoarthritis, left knee |
| M17.2 | Bilateral post-traumatic osteoarthritis of knee |
| M17.31 | Unilateral post-traumatic osteoarthritis, right knee |
| M17.32 | Unilateral post-traumatic osteoarthritis, left knee |
| M17.4 | Other bilateral secondary osteoarthritis of knee |
| M17.5 | Other unilateral secondary osteoarthritis of knee |
| M17.9 | Osteoarthritis of knee, unspecified |
| M19.011 | Primary osteoarthritis, right shoulder |
| M19.012 | Primary osteoarthritis, left shoulder |
| M19.111 | Post-traumatic osteoarthritis, right shoulder |
| M19.112 | Post-traumatic osteoarthritis, left shoulder |
| M19.211 | Secondary osteoarthritis, right shoulder |
| M19.212 | Secondary osteoarthritis, left shoulder |
| M75.41 | Impingement syndrome of right shoulder |
| M75.42 | Impingement syndrome of left shoulder |
Procedure codes: 20610, 20611, J7318 (Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg), J7320 (Hyaluronan or derivitive, genvisc 850, for intra-articular injection, 1 mg), J7321 (Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose), J7322 (Hyaluronan or derivative, hymovis or hymovis one, for intra-articular injection, 1 mg), J7323 (Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose), J7324 (Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose), J7325 (Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg), J7326 (Hyaluronan or derivative, gel-one, for intra-articular injection, per dose), J7327 (Hyaluronan or derivative, monovisc, for intra-articular injection, per dose), J7328 (Hyaluronan or derivative, gelsyn-3, for intra-articular injection, 0.1 mg), J7329 (Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg), J7331 (Hyaluronan or derivative, synojoynt, for intra-articular injection, 1 mg), J7332 (Hyaluronan or derivative, triluron, for intra-articular injection, 1 mg).
A52421: Billing and Coding: Ibandronate Sodium (Billing and Coding, effective 2026-04-01)
- Covered ICD-10-CM codes
- 254
- 5 groups
- Non-covered ICD-10-CM codes
- 0
- Procedure codes listed
- 1
- Full article
- cms.gov record
| ICD-10-CM | Description (FY2027) |
|---|---|
| C79.51 | Secondary malignant neoplasm of bone |
| E28.310 | Symptomatic premature menopause |
| E28.319 | Asymptomatic premature menopause |
| E83.52 | Hypercalcemia |
| E89.40 | Asymptomatic postprocedural ovarian failure |
| E89.41 | Symptomatic postprocedural ovarian failure |
| K20.80 | Other esophagitis without bleeding |
| K20.81 | Other esophagitis with bleeding |
| K20.90 | Esophagitis, unspecified without bleeding |
| K20.91 | Esophagitis, unspecified with bleeding |
| M80.011A | Age-related osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture |
| M80.011D | Age-related osteoporosis with current pathological fracture, right shoulder, subsequent encounter for fracture with routine healing |
| M80.011G | Age-related osteoporosis with current pathological fracture, right shoulder, subsequent encounter for fracture with delayed healing |
| M80.011K | Age-related osteoporosis with current pathological fracture, right shoulder, subsequent encounter for fracture with nonunion |
| M80.011P | Age-related osteoporosis with current pathological fracture, right shoulder, subsequent encounter for fracture with malunion |
| M80.011S | Age-related osteoporosis with current pathological fracture, right shoulder, sequela |
| M80.012A | Age-related osteoporosis with current pathological fracture, left shoulder, initial encounter for fracture |
| M80.012D | Age-related osteoporosis with current pathological fracture, left shoulder, subsequent encounter for fracture with routine healing |
| M80.012G | Age-related osteoporosis with current pathological fracture, left shoulder, subsequent encounter for fracture with delayed healing |
| M80.012K | Age-related osteoporosis with current pathological fracture, left shoulder, subsequent encounter for fracture with nonunion |
| M80.012P | Age-related osteoporosis with current pathological fracture, left shoulder, subsequent encounter for fracture with malunion |
| M80.012S | Age-related osteoporosis with current pathological fracture, left shoulder, sequela |
| M80.021A | Age-related osteoporosis with current pathological fracture, right humerus, initial encounter for fracture |
| M80.021D | Age-related osteoporosis with current pathological fracture, right humerus, subsequent encounter for fracture with routine healing |
Procedure codes: J1740 (Injection, ibandronate sodium, 1 mg).
A52423: Billing and Coding: Infliximab and biosimilars (Billing and Coding, effective 2026-04-01)
- Covered ICD-10-CM codes
- 619
- 5 groups
- Non-covered ICD-10-CM codes
- 0
- Procedure codes listed
- 4
- Full article
- cms.gov record
| ICD-10-CM | Description (FY2027) |
|---|---|
| A18.54 | Tuberculous iridocyclitis |
| D86.0 | Sarcoidosis of lung |
| D86.1 | Sarcoidosis of lymph nodes |
| D86.2 | Sarcoidosis of lung with sarcoidosis of lymph nodes |
| D86.3 | Sarcoidosis of skin |
| D86.81 | Sarcoid meningitis |
| D86.82 | Multiple cranial nerve palsies in sarcoidosis |
| D86.83 | Sarcoid iridocyclitis |
| D86.84 | Sarcoid pyelonephritis |
| D86.85 | Sarcoid myocarditis |
| D86.86 | Sarcoid arthropathy |
| D86.87 | Sarcoid myositis |
| D86.89 | Sarcoidosis of other sites |
| D86.9 | Sarcoidosis, unspecified |
| D89.810 | Acute graft-versus-host disease |
| D89.812 | Acute on chronic graft-versus-host disease |
| H20.00 | Unspecified acute and subacute iridocyclitis |
| H20.011 | Primary iridocyclitis, right eye |
| H20.012 | Primary iridocyclitis, left eye |
| H20.013 | Primary iridocyclitis, bilateral |
| H20.019 | Primary iridocyclitis, unspecified eye |
| H20.021 | Recurrent acute iridocyclitis, right eye |
| H20.022 | Recurrent acute iridocyclitis, left eye |
| H20.023 | Recurrent acute iridocyclitis, bilateral |
Procedure codes: J1745 (Injection, infliximab, excludes biosimilar, 10 mg), Q5103 (Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg), Q5104 (Injection, infliximab-abda, biosimilar, (renflexis), 10 mg), Q5121 (Injection, infliximab-axxq, biosimilar, (avsola), 10 mg).
A52448: Billing and Coding: Omalizumab and biosimilar, OMLYCLO® (omalizumab-igec) (Billing and Coding, effective 2026-04-01)
- Covered ICD-10-CM codes
- 17
- 1 group
- Non-covered ICD-10-CM codes
- 0
- Procedure codes listed
- 2
- Full article
- cms.gov record
| ICD-10-CM | Description (FY2027) |
|---|---|
| J33.0 | Polyp of nasal cavity |
| J45.40 | Moderate persistent asthma, uncomplicated |
| J45.41 | Moderate persistent asthma with (acute) exacerbation |
| J45.42 | Moderate persistent asthma with status asthmaticus |
| J45.50 | Severe persistent asthma, uncomplicated |
| J45.51 | Severe persistent asthma with (acute) exacerbation |
| J45.52 | Severe persistent asthma with status asthmaticus |
| L50.1 | Idiopathic urticaria |
| L50.6 | Contact urticaria |
| L50.8 | Other urticaria |
| L50.9 | Urticaria, unspecified |
| T78.40XA | Allergy, unspecified, initial encounter |
| T78.40XD | Allergy, unspecified, subsequent encounter |
| T78.40XS | Allergy, unspecified, sequela |
| Z91.010 | Allergy to peanuts |
| Z91.013 | Allergy to seafood |
| Z91.040 | Latex allergy status |
Procedure codes: J2357 (Injection, omalizumab, 5 mg), Q5154 (Injection, omalizumab-igec (omlyclo), biosimilar, 5 mg).
A52450: Billing and Coding: Paclitaxel (e.g., Taxol®/Abraxane ™) (Billing and Coding, effective 2026-04-01)
- Covered ICD-10-CM codes
- 699
- 2 groups
- Non-covered ICD-10-CM codes
- 0
- Procedure codes listed
- 2
- Full article
- cms.gov record
| ICD-10-CM | Description (FY2027) |
|---|---|
| C00.0 | Malignant neoplasm of external upper lip |
| C00.1 | Malignant neoplasm of external lower lip |
| C00.2 | Malignant neoplasm of external lip, unspecified |
| C00.3 | Malignant neoplasm of upper lip, inner aspect |
| C00.4 | Malignant neoplasm of lower lip, inner aspect |
| C00.5 | Malignant neoplasm of lip, unspecified, inner aspect |
| C00.6 | Malignant neoplasm of commissure of lip, unspecified |
| C00.8 | Malignant neoplasm of overlapping sites of lip |
| C00.9 | Malignant neoplasm of lip, unspecified |
| C01 | Malignant neoplasm of base of tongue |
| C02.0 | Malignant neoplasm of dorsal surface of tongue |
| C02.1 | Malignant neoplasm of border of tongue |
| C02.2 | Malignant neoplasm of ventral surface of tongue |
| C02.3 | Malignant neoplasm of anterior two-thirds of tongue, part unspecified |
| C02.4 | Malignant neoplasm of lingual tonsil |
| C02.8 | Malignant neoplasm of overlapping sites of tongue |
| C02.9 | Malignant neoplasm of tongue, unspecified |
| C03.0 | Malignant neoplasm of upper gum |
| C03.1 | Malignant neoplasm of lower gum |
| C03.9 | Malignant neoplasm of gum, unspecified |
| C04.0 | Malignant neoplasm of anterior floor of mouth |
| C04.1 | Malignant neoplasm of lateral floor of mouth |
| C04.8 | Malignant neoplasm of overlapping sites of floor of mouth |
| C04.9 | Malignant neoplasm of floor of mouth, unspecified |
Procedure codes: J9264 (Injection, paclitaxel protein-bound particles, 1 mg), J9267 (Injection, paclitaxel, 1 mg).
A52451: Billing and Coding: Ranibizumab, Aflibercept and biosimilars (Billing and Coding, effective 2026-07-01)
- Covered ICD-10-CM codes
- 230
- 6 groups
- Non-covered ICD-10-CM codes
- 0
- Procedure codes listed
- 20
- Full article
- cms.gov record
| ICD-10-CM | Description (FY2027) |
|---|---|
| E08.311 | Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema |
| E08.319 | Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema |
| E08.3211 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye |
| E08.3212 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye |
| E08.3213 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral |
| E08.3291 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right eye |
| E08.3292 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left eye |
| E08.3293 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, bilateral |
| E08.3311 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye |
| E08.3312 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye |
| E08.3313 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral |
| E08.3391 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, right eye |
| E08.3392 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, left eye |
| E08.3393 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, bilateral |
| E08.3411 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye |
| E08.3412 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye |
| E08.3413 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral |
| E08.3491 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, right eye |
| E08.3492 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, left eye |
| E08.3493 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, bilateral |
| E08.3511 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye |
| E08.3512 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye |
| E08.3513 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral |
| E08.3521 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye |
Procedure codes: 67027, 67028, C9399 (Unclassified drugs or biologicals), J0177 (Injection, aflibercept hd, 1 mg), J0178 (Injection, aflibercept, 1 mg), J0179 (Injection, brolucizumab-dbll, 1 mg), J2777 (Injection, faricimab-svoa, 0.1 mg), J2778 (Injection, ranibizumab, 0.1 mg), J2779 (Injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg), J3490 (Unclassified drugs), J3590 (Unclassified biologics), Q5124 (Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg), Q5128 (Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg), Q5147 (Injection, aflibercept-ayyh (pavblu), biosimilar, 1 mg), Q5149 (Injection, aflibercept-abzv (enzeevu), biosimilar, 1 mg), Q5150 (Injection, aflibercept-mrbb (ahzantive), biosimilar, 1 mg), Q5153 (Injection, aflibercept-yszy (opuviz), biosimilar, 1 mg), Q5155 (Injection, aflibercept-jbvf (yesafili), biosimilar, 1 mg), Q5168 (Injection, ranibizumab-leyk (nufymco), biosimilar, 0.1 mg), Q5170 (Injection, aflibercept-boav (eydenzelt), biosimilar, 1 mg).
A52453: Billing and Coding: Luteinizing Hormone-Releasing Hormone (LHRH) Analogs (Billing and Coding, effective 2026-04-01)
- Covered ICD-10-CM codes
- 207
- 14 groups
- Non-covered ICD-10-CM codes
- 0
- Procedure codes listed
- 14
- Full article
- cms.gov record
| ICD-10-CM | Description (FY2027) |
|---|---|
| C07 | Malignant neoplasm of parotid gland |
| C08.0 | Malignant neoplasm of submandibular gland |
| C08.1 | Malignant neoplasm of sublingual gland |
| C48.1 | Malignant neoplasm of specified parts of peritoneum |
| C48.8 | Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum |
| C50.011 | Malignant neoplasm of nipple and areola, right female breast |
| C50.012 | Malignant neoplasm of nipple and areola, left female breast |
| C50.021 | Malignant neoplasm of nipple and areola, right male breast |
| C50.022 | Malignant neoplasm of nipple and areola, left male breast |
| C50.111 | Malignant neoplasm of central portion of right female breast |
| C50.112 | Malignant neoplasm of central portion of left female breast |
| C50.121 | Malignant neoplasm of central portion of right male breast |
| C50.122 | Malignant neoplasm of central portion of left male breast |
| C50.211 | Malignant neoplasm of upper-inner quadrant of right female breast |
| C50.212 | Malignant neoplasm of upper-inner quadrant of left female breast |
| C50.221 | Malignant neoplasm of upper-inner quadrant of right male breast |
| C50.222 | Malignant neoplasm of upper-inner quadrant of left male breast |
| C50.311 | Malignant neoplasm of lower-inner quadrant of right female breast |
| C50.312 | Malignant neoplasm of lower-inner quadrant of left female breast |
| C50.321 | Malignant neoplasm of lower-inner quadrant of right male breast |
| C50.322 | Malignant neoplasm of lower-inner quadrant of left male breast |
| C50.411 | Malignant neoplasm of upper-outer quadrant of right female breast |
| C50.412 | Malignant neoplasm of upper-outer quadrant of left female breast |
| C50.421 | Malignant neoplasm of upper-outer quadrant of right male breast |
Procedure codes: 11981, 11982, 11983, 96402, J1950 (Injection, leuprolide acetate (for depot suspension), per 3.75 mg), J1952 (Leuprolide injectable, camcevi, 1 mg), J1954 (Injection, leuprolide acetate for depot suspension (lutrate depot), 7.5 mg), J3315 (Injection, triptorelin pamoate, 3.75 mg), J3316 (Injection, triptorelin, extended-release, 3.75 mg), J9202 (Goserelin acetate implant, per 3.6 mg), J9217 (Leuprolide acetate (for depot suspension), 7.5 mg), J9218 (Leuprolide acetate, per 1 mg), J9219 (Leuprolide acetate implant, 65 mg), J9225 (Histrelin implant (vantas), 50 mg).
A54548: Billing and Coding: Eculizumab, and Biosimilars: EPYSQLI®-eculizumab-aagh, and BKEMV™-eculizumab-aeeb (Billing and Coding, effective 2026-04-01)
- Covered ICD-10-CM codes
- 18
- 1 group
- Non-covered ICD-10-CM codes
- 0
- Procedure codes listed
- 3
- Full article
- cms.gov record
| ICD-10-CM | Description (FY2027) |
|---|---|
| D59.31 | Infection-associated hemolytic-uremic syndrome |
| D59.32 | Hereditary hemolytic-uremic syndrome |
| D59.39 | Other hemolytic-uremic syndrome |
| D59.5 | Paroxysmal nocturnal hemoglobinuria [Marchiafava-Micheli] |
| G36.0 | Neuromyelitis optica [Devic] |
| G70.00 | Myasthenia gravis without (acute) exacerbation |
| G70.01 | Myasthenia gravis with (acute) exacerbation |
| N00.6 | Acute nephritic syndrome with dense deposit disease |
| N00.B1 | Acute nephritic syndrome with idiopathic immune membranoproliferative glomerulonephritis (IC-MPGN) |
| N00.B2 | Acute nephritic syndrome with secondary immune complex membranoproliferative glomerulonephritis (IC-MPGN) |
| N01.6 | Rapidly progressive nephritic syndrome with dense deposit disease |
| N02.6 | Recurrent and persistent hematuria with dense deposit disease |
| N03.6 | Chronic nephritic syndrome with dense deposit disease |
| N04.6 | Nephrotic syndrome with dense deposit disease |
| N04.B1 | Nephrotic syndrome with idiopathic immune complex membranoproliferative glomerulonephritis (IC-MPGN) |
| N04.B2 | Nephrotic syndrome with secondary immune complex membranoproliferative glomerulonephritis (IC-MPGN) |
| N07.6 | Hereditary nephropathy, not elsewhere classified with dense deposit disease |
| T86.19 | Other complication of kidney transplant |
Procedure codes: J1299 (Injection, eculizumab, 2 mg), Q5151 (Injection, eculizumab-aagh (epysqli), biosimilar, 2 mg), Q5152 (Injection, eculizumab-aeeb (bkemv), biosimilar, 2 mg).
Coverage indications, limitations and medical necessity
Abstract:
An off-label/unlabeled use of a drug is defined as a use for a non-FDA approved indication, that is, one that is not listed on the drug's official label/prescribing information. An indication is defined as a diagnosis, illness, injury, syndrome, condition, or other clinical parameter for which a drug may be given. Off-label use is further defined as giving the drug in a way that deviates significantly from the labeled prescribing information for a particular indication. This includes but is not necessarily limited to, dosage, route of administration, duration and frequency of administration, and population to whom the drug would be administered. Drugs used for indications other than those in the approved labeling may be covered under Medicare if it is determined that the use is medically accepted, taking into consideration the major drug compendia, authoritative medical literatures and/or accepted standards of medical practice. Determinations as to whether medication is reasonable and necessary for an individual patient are made on appeal on the same basis as all other such determinations (i.e., with support from the peer-reviewed literature, with the advice of medical consultants, with reference to accepted standards of medical practice, and in consideration of the medical circumstance of the individual case).
In the case of drugs used in an anti-cancer chemotherapeutic regimen, off-label uses are covered for a medically accepted indication as defined in the Medicare Benefit Policy Manual (CMS publication 100-2, Chapter 15, Section 50.4.5).
In order to meet the requirement that the use of the drug is reasonable and necessary for the treatment of disease, the drugs must be safe and effective. Drugs approved for marketing by the Food and Drug Administration (FDA) are considered safe and effective when used for indications specified on the labeling. Therefore, Medicare pays for the use of a FDA-approved drug, if:
• It was injected on or after the date of the FDA's approval;
• It is reasonable and necessary for the individual patient; and
• All other applicable coverage requirements are met.
Indications:
A medically accepted indication, which is covered by National Government Services is one of the following:
• An FDA approved, labeled indication or a use supported in the American Hospital Formulary Service Drug Information (AHFS-DI), NCCN Drugs and Biologics Compendium, Truven Health Analytics Micromedex DrugDex®, Elsevier/Gold Standard Clinical Pharmacology and Wolters Kluwer Lexi-Drugs® as the acceptable compendia based on CMS' Change Request 6191 (Compendia as Authoritative Sources for Use in the Determination of a "Medically Accepted Indication" of Drugs and Biologicals Used Off-Label in an Anti-Cancer Chemotherapeutic Regimen); or
• Articles or Local Coverage Determinations (LCDs) published by National Government Services.
The compendia listed above will be accepted at the following levels;
• American Hospital Formulary Service-Drug Information (AHFS-DI) – indication is supportive
• NCCN Drugs and Biologics Compendium - indication is a Category 1 or 2A
• Micromedex DrugDex® – indication is Class I, Class IIa, or Class IIb or
• Clinical Pharmacology – indication is supportive
• Lexi-Drugs - indication is rated as “Evidence Level A”
When new off-label uses for drugs are published in the above compendia at the accepted level of recommendation, the effective date for National Government Services coverage of those off-label uses is the date of publication of our revised coverage article, not the date of inclusion in the compendia.
In an effort to limit the number of LCD's or articles related to off label indications for drug use, National Government Services will publish articles relating to drugs approved for off-label use for which there is a need for education or concern about utilization. These articles will include drugs with links to their FDA approved and compendia approved uses as listed in the American Hospital Formulary Services (AHFS), Elsevier/Gold Standard Clinical Pharmacology, NCCN Drugs and Biologics Compendium, Truven Health Analytics Micromedex DrugDex® compendium and/or Wolters Kluwer Lexi-Drugs®. Only off-label uses requested by providers according to the following criteria will be considered for inclusion.
Providers may request that a drug be approved for off-label use by submitting this request in writing and including the data supporting its use. The data must include:
• A use supported by clinical research that appears in at least two Phase III clinical trials that definitively demonstrate safety and effectiveness; or,
• If no Phase III trial evidence is available, at least two Phase II clinical trials with reasonably large patient samples showing consistent results of safety and efficacy may be considered in certain instances such as use in rare diseases in which a Phase III study might be difficult to complete in a reasonable period of time after completion of the Phase II studies, or when overwhelmingly good evidence of safety and effectiveness is noted in the Phase II studies.
• A use that is an accepted standard of medical practice. "Are there published recommendations from specialty societies or in other authoritative evidence-based guidelines?" (For example, a state of the art review article published in a recognized textbook or a reputable publication) It should be noted that acceptance by individual health care practitioners, or even a limited group of health care practitioners normally does not indicate general acceptance by the medical community. Testimonials indicating such limited acceptance, and limited case studies distributed by sponsors with potential financial conflict of interest in the outcome, are not sufficient evidence of general acceptance by the medical community. The broad range of available evidence must be considered and its quality must be evaluated before a conclusion is reached.
The Phase III or Phase II trials must come from different centers and be published in national or international peer-reviewed (editorial committee is comprised of physicians) journals. Peer reviewed medical literature includes scientific and medical publications. It does not include in-house publications of pharmaceutical manufacturing companies or abstracts (including meeting abstracts).
In principle, rankings of research design have been based on the ability of each study design category to minimize bias. The following is a representative list of study designs (some of which have alternative names) ranked from most to least methodologically rigorous in their potential ability to minimize systematic bias:
• Randomized controlled trials
• Non-randomized controlled trials
• Prospective cohort studies
• Retrospective case control studies
• Cross-sectional studies
• Surveillance studies (e.g., using registries or surveys)
• Consecutive case series and
• Single case reports
The design, conduct and analysis of trials are important factors as well. For example, a well designed and conducted observational study with a large sample size may provide stronger evidence than a poorly designed and conducted randomized controlled trial with a small sample size.
In determining whether there is supportive clinical evidence for a particular use of a drug, the quality of the published evidence must be considered. Such consideration involves the assessment of the following study characteristics:
• The adequacy of the number of subjects;
• The response rate;
• The effect on key status and survival indications. That is, the effect on the patient's well-being and other responses to therapy that indicate effectiveness (e.g., reduction in mortality, morbidity, signs and symptoms);
• The appropriateness of the study design, that is, whether the experimental design in light of the drugs and conditions under investigation is appropriate to address the investigative question. (For example, in some clinical studies, it may be unnecessary or not feasible to use randomization, double blind trials, placebos, or crossover.); and
• The prevalence and life history of the disease when evaluating the adequacy of the number of subjects and the response rate.
After such evidence is received, National Government Services will, with appropriate help of specialty-specific consultants as indicated, make a coverage determination for the non-FDA approved indication (off-label use) of the drug or biological.
National Government Services may determine a drug use to be reasonable and necessary for the treatment of illness or injury if, on the basis of available or presented evidence, if it is shown to be safe and effective and does not violate national or local Medicare determinations and regulations. The approval will include, but is not limited to, diagnosis, dose and route of administration, duration and frequency, and appropriate patient population.
Limitations:
If a use is identified as not indicated by CMS or the FDA, or if a use is specifically identified as not indicated in the American Hospital Formulary Services (AHFS), Elsevier/Gold Standard Clinical Pharmacology, NCCN Drugs and Biologics Compendium, Truven Health Analytics Micromedex DrugDex® and/or Wolters Kluwer Lexi-Drugs® compendium, the off-label use is not supported and the drug will not be covered.
Regardless of the evidence supporting coverage for a particular off-label use, payment may only be made if the use is reasonable and necessary for the treatment of illness or injury of the specific patient receiving the drug.
Services related to non-covered services or drugs are also not covered (e.g., administration services).
Upon review, if the drug use is not on the FDA label, does not appear on the American Hospital Formulary Services (AHFS), Elsevier/Gold Standard Clinical Pharmacology, NCCN Drugs and Biologics Compendium, Truven Health Analytics Micromedex DrugDex® and/or Wolters Kluwer Lexi-Drugs® compendium or National Government Services has not published an LCD or article covering the off-label use as listed below, then the drug use is not approved and the use of the drug may be denied. However, determinations as to whether medication is reasonable and necessary for an individual patient may be made on appeal on the same basis as all other such determinations (i.e., with support from the peer-reviewed literature, with the advice of medical consultants, with reference to accepted standards of medical practice, and in consideration of the medical circumstance of the individual case).
The route of administration must be reasonable and necessary as well as the drug. (Pub 100-02, Medicare Benefit Policy Manual, Chapter 15, Section 50.2 - Determining Self-Administration of Drug or Biological (Rev. 91; Issued: 06-20-08; Effective/Implementation Date: 07-21-08)). National Government Services will use evidence-based clinical guidelines to determine medical necessity of the route of administration.
Specific Drugs and Biological Coverage
FDA and approved Compendia Uses
The following drugs will be covered for their FDA approved uses as well as their approved compendia uses.
Denosumab (Prolia ™, Xgeva ™)
Hyaluronans Intra-articular Injections of
Omalizumab
Ranibizumab and Aflibercept
FDA, approved Compendia and Off-label Uses
The following drug will be covered for off label uses described below in addition to their FDA approved use and approved compendia uses.
Bevacizumab and biosimilars-NGS has approved bevacizumab for treating hereditary hemorrhagic telangiectasia (HHT) with arteriovenous malformations (AVMs).
Eculizumab - NGS has approved eculizumab for biopsy proven dense deposit disease.
Ibandronate Sodium - NGS has approved ibandronate for senile osteoporosis in male patients.
Infliximab and biosimilars - NGS has approved infliximab for the following:
• Behçet’s Disease (BD), also known as Behçet’s Syndrome, in patients without an adequate response to initial therapy, for the treatment of clinical manifestations of BD such as severe ocular involvement, major organ involvement, severe gastrointestinal or neurological involvement and resistant cases of joint or mucocutaneous involvement (i.e., painful oral and genital ulcers).
• Pyoderma gangrenosum with coexisting inflammatory bowel disease.
• Sarcoid refractory to treatment with steroids and other standard drug regimens.
• Severe immune-related colitis that does not respond promptly (within 1 week) to therapy with high-dose steroids. A single dose of infliximab is sufficient to resolve immune-related colitis in most patients.
• Treatment of microscopic colitis deemed refractory because of lack of response to standard pharmacologic therapy.
Luteinizing Hormone-Releasing Hormone (LHRH) Analogs - NGS has approved Leuprolide Acetate for the following:
• Carcinoma, breast (treatment): palliative treatment of advanced breast carcinoma in premenopausal and perimenopausal women
• Suspected endometriosis causing chronic (6 months or more) pelvic pain after an appropriate pretreatment evaluation (to exclude other causes) and failure of initial treatment with OCs and NSAIDs; not to continue beyond 3 months if there is not significant symptomatic improvement
• Head and Neck cancers-salivary gland tumors
Goserelin Acetate - NGS has approved Goserelin Acetate for the following:
• Treatment of leiomyomata: 3.6 mg per month for short duration (3-6 months).
Paclitaxel (e.g., Taxol®/Abraxane ™) - NGS has approved paclitaxel for the following:
• Hormone refractory prostate carcinoma
• Carcinoma of the renal pelvis and ureter
• Rhabdomyosarcoma
• Leiomyosarcoma
Summary of evidence (opening)
Off Label Use of Bevacizumab
The use of bevacizumab in hereditary hemorrhagic telangiectasia (HHT) with arteriovenous malformations (AVMs) causing gastrointestinal bleeding is supported by several studies, highlighting its efficacy in reducing transfusion requirements and improving hemoglobin levels. The HHT Foundation’s policy statement underscores the drug’s ability to reduce the need for red blood cell transfusions and iron infusions in HHT patients suffering from severe gastrointestinal bleeding, with recommended dosing and close follow-up for tailored treatment (HHT Foundation, 2020). This guideline reflects the expert consensus on its use, although it also acknowledges the off-label nature of this application (Hammill et al., 2021).
Further evidence from clinical studies corroborates these findings, demonstrating significant improvements in clinical outcomes with bevacizumab treatment. The InHIBIT-Bleed trial, a prospective, multicenter study, reported a substantial reduction in epistaxis severity, an increase in hemoglobin levels, and decreased transfusion requirements, emphasizing the drug’s role in managing severe bleeding in HHT (Al-Samkari et al., 2021). Additionally, a retrospective study highlighted similar benefits in patients with gastric antral vascular ectasia and small bowel angioectasia, showing a dramatic decrease in transfusion needs and endoscopic interventions following bevacizumab treatment, albeit with the necessity for "top-up" doses in some cases (Albitar et al., 2020). These studies collectively suggest that bevacizumab is an effective intervention for managing severe gastrointestinal bleeding in HHT.
the full summary and analysis of evidence are in the CMS record.
Dates, lineage and related policies
- Original determination effective
- 2015-10-01
- Current revision effective
- 2026-07-13
- MCD version
- 55
- Derived from
- L25820
Other related documents: A52855 (Billing and Coding), A59983 (Response to Comments).
Using this policy on a claim
Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Wellpoint Federal hub lists every other active policy from the same contractor.
For teams evaluating QuickIntell software
Where QuickIntell fits with this policy
If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.
Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.
Frequently asked questions
What does LCD L33394 cover?
An off-label/unlabeled use of a drug is defined as a use for a non-FDA approved indication, that is, one that is not listed on the drug's official label/prescribing information. An indication is defined as a diagnosis, illness, injury, syndrome, condition, or other clinical parameter for which a drug may be given. Off-label use is further defined as giving the drug in a way that deviates significantly… The full 2,024-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.
Which states does LCD L33394 apply to?
Wellpoint Federal applies it to Medicare claims in 10 states: CT, IL, MA, ME, MN, NH, NY, RI, VT, WI. It binds only that contractor; outside these jurisdictions the same service is judged under the local contractor's own policy or, where none exists, claim by claim.
Which diagnosis codes support medical necessity under LCD L33394?
The companion billing and coding article A52370 lists 458 ICD-10-CM codes in 2 groups that support medical necessity; the first 24 appear on this page, where the complete list opens by group with the contractor's group instructions.
How do I appeal a denial under LCD L33394?
A denial under LCD L33394 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A52370's 458 covered diagnosis codes, then file a redetermination with Wellpoint Federal within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.
- Medicare Coverage Database, current LCD exportVersion MCD release 2026-11-12 · effective 2026-11-08 · file lcd.csvSHA-256 2e0eda3351aa3d47…
- Medicare Coverage Database, current Billing and Coding Articles exportVersion MCD release 2026-11-12 · effective 2026-11-08 · file article.csvSHA-256 b475751458564786…
- ICD-10-CM FY2027 code descriptionsVersion FY2027 · effective 2026-10-01 · file icd10cm_codes_2027.txtSHA-256 3c0583a38ee0e848…
Disclaimer
The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.
Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.